Fund Details
Overview
Investment portfolio
16rounds
| NAME | DATE | SIZE | |
|---|---|---|---|
Sanegene Bio | Dec 2025Participated | $110 MSeries B | |
Mol Breeding | Jul 2024Participated | $34 MSeries B | |
Bang Er Orthopedic | Nov 2023Participated | $110 MOther Equity | |
HC Scientific | Aug 2023Led | $41 MSeries B | |
CoJourney | Jul 2023Participated | $30 MSeries A | |
BANGBANG ROBOT | Jun 2022Led | $15 MSeries B | |
GenFleet Therapeutics | Jan 2022Participated | $79 MSeries C | |
Meditrust | Aug 2021Participated | $309 MSeries C | |
Lupeng Pharmaceutical | Jul 2021Participated | $35 MSeries B | |
Exegenesis Bio | Jun 2021Participated | $50 MSeries B | |
Insilico Medicine | Jun 2021Participated | $255 MSeries C | |
WeMed | Apr 2021Led | $46 MSeries D | |
Sanegene Bio | Dec 2025Participated | $110 MSeries B | |
Mol Breeding | Jul 2024Participated | $34 MSeries B | |
Bang Er Orthopedic | Nov 2023Participated | $110 MOther Equity | |
HC Scientific | Aug 2023Led | $41 MSeries B | |
CoJourney | Jul 2023Participated | $30 MSeries A | |
BANGBANG ROBOT | Jun 2022Led | $15 MSeries B | |
GenFleet Therapeutics | Jan 2022Participated | $79 MSeries C | |
Meditrust | Aug 2021Participated | $309 MSeries C | |
Lupeng Pharmaceutical | Jul 2021Participated | $35 MSeries B | |
Exegenesis Bio | Jun 2021Participated | $50 MSeries B | |
Insilico Medicine | Jun 2021Participated | $255 MSeries C | |
WeMed | Apr 2021Led | $46 MSeries D |
16 Items
16
Items
...
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 0 | 1 |
| Series B | 3 | 4 |
| Series C+ | 1 | 5 |
| Other Equity | 1 | 1 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Nov '19 | 1 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 1 |
| May '20 | 0 |
| Jun '20 | 0 |
| Jul '20 | 0 |
| Aug '20 | 0 |
| Sep '20 | 0 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 0 |
| Feb '21 | 0 |
| Mar '21 | 2 |
| Apr '21 | 1 |
| May '21 | 0 |
| Jun '21 | 2 |
| Jul '21 | 1 |
| Aug '21 | 1 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 1 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 1 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 1 |
| Aug '23 | 1 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 1 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 1 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 1 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 16 |
| Fintech | 2 |
| AI & Machine Learning | 2 |
| Professional Services | 2 |
| Hardware & Robotics | 1 |
| Manufacturing | 1 |
| Food & Agriculture | 1 |
| Consumer & Lifestyle | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 0 |
| $10M-$25M | 1 |
| $25M-$50M | 5 |
| $50M-$100M | 2 |
| $100M-$250M | 6 |
| $250M-$500M | 2 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 4 of 4 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| China | 9 |
| United States | 5 |
| Russian Federation | 1 |
| South Africa | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Lilly Asia Ventures | 4 |
| OrbiMed | 3 |
| AIHC Capital | 2 |
| Baidu Ventures | 2 |
| CPE | 2 |
| Janchor Partners | 2 |
| Legend Capital | 2 |
| Legend Star | 2 |
| Loyal Valley Capital | 2 |
| Qiming Venture Partners | 2 |
| Sino Biopharmaceutical | 2 |
| Sinovation Ventures | 2 |
| TF Capital | 2 |
| Vivo Capital | 2 |
| 01VC | 1 |
| B Capital Group | 1 |
| Bank of China Group Investment | 1 |
| Bold Capital Partners | 1 |
| Boyu Capital | 1 |
| CBC Group | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 5 | 31% |
| Participating | 11 | 69% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 4 | 80% |
| Co-led | 1 | 20% |
Team
Bin Li
Founding Partner and CEO